Meta-analyses of patients with low-volume metastatic hormone-sensitive prostate cancer will likely be required to attain sufficient power to address the role of docetaxel in this setting.
Andrew J. Armstrong, MD, ScM, FACP
Advertisement
Articles by Andrew J. Armstrong, MD, ScM, FACP
Advertisement
Latest Updated Articles
In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? No, Not YetPublished: October 15th 2014 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
3
Career Stage and Location Found to Impact Oncology Coverage in the US
4
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
5
